LONGBIO-B (01779.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 101.90

From 52W high−33.21%

Volume168900.00

Market capHKD 7.88B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 101.90

From 52W high

−33.21%

Volume

168900.00

Market cap

HKD 7.88B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

46.7

MomentumView details →

1D Return

+3.04%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+3.04%

YTD Return

—

1Y Return

—

RSI (14)

46.7

vs 50D SMA

−1.46%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Tianchen Biopharmaceutical announced its interim results for the six months ended June 2026, reporting a net loss of RMB 135 million, wider than the RMB 94.208 million loss in the same period last year, with a loss per share of RMB 2.18 and no dividend.30d ago

Tianchen Biopharmaceutical-B announced that its self-developed anti-IgE antibody LP-003 for seasonal allergic rhinitis has had its Biologics License Application accepted by China's National Medical Products Administration.31d ago

Similar companies

Spyre Therapeutics, Inc.SYRE Immunovant, Inc.IMVT 苑东生物688513.SH Alphamab Oncology09966.HK Praxis Precision Medicines, Inc.PRAX CStone Pharmaceuticals02616.HK Find similar companies →

Latest newsMore news →

Tianchen Biopharmaceutical announced its interim results for the six months ended June 2026, reporting a net loss of RMB 135 million, wider than the RMB 94.208 million loss in the same period last year, with a loss per share of RMB 2.18 and no dividend.30d ago Tianchen Biopharmaceutical-B announced that its self-developed anti-IgE antibody LP-003 for seasonal allergic rhinitis has had its Biologics License Application accepted by China's National Medical Products Administration.31d ago